These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 33620131)

  • 1. Haemodynamic effects of the nitroxyl donor cimlanod (BMS-986231) in chronic heart failure: a randomized trial.
    Lang NN; Ahmad FA; Cleland JG; O'Connor CM; Teerlink JR; Voors AA; Taubel J; Hodes AR; Anwar M; Karra R; Sakata Y; Ishihara S; Senior R; Khemka A; Prasad NG; DeSouza MM; Seiffert D; Ye JY; Kessler PD; Borentain M; Solomon SD; Felker GM; McMurray JJV
    Eur J Heart Fail; 2021 Jul; 23(7):1147-1155. PubMed ID: 33620131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of a Novel Nitroxyl Donor in Acute Heart Failure: The STAND-UP AHF Study.
    Felker GM; McMurray JJV; Cleland JG; O'Connor CM; Teerlink JR; Voors AA; Belohlavek J; Böhm M; Borentain M; Bueno H; Cole RT; DeSouza MM; Ezekowitz JA; Filippatos G; Lang NN; Kessler PD; Martinez FA; Mebazaa A; Metra M; Mosterd A; Pang PS; Ponikowski P; Sato N; Seiffert D; Ye J
    JACC Heart Fail; 2021 Feb; 9(2):146-157. PubMed ID: 33248986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of vasodilators on diuretic response in patients with congestive heart failure: A mechanistic trial of cimlanod (BMS-986231).
    Pellicori P; Cleland JGF; Borentain M; Taubel J; Graham FJ; Khan J; Bruzzese D; Kessler P; McMurray JJV; Voors AA; O'Connor CM; Teerlink JR; Felker GM
    Eur J Heart Fail; 2024 Jan; 26(1):142-151. PubMed ID: 37990754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Phase 2a dose-escalation study of the safety, tolerability, pharmacokinetics and haemodynamic effects of BMS-986231 in hospitalized patients with heart failure with reduced ejection fraction.
    Tita C; Gilbert EM; Van Bakel AB; Grzybowski J; Haas GJ; Jarrah M; Dunlap SH; Gottlieb SS; Klapholz M; Patel PC; Pfister R; Seidler T; Shah KB; Zieliński T; Venuti RP; Cowart D; Foo SY; Vishnevsky A; Mitrovic V
    Eur J Heart Fail; 2017 Oct; 19(10):1321-1332. PubMed ID: 28677877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of transdermal nitroglycerin in children with congestive heart failure: a Doppler echocardiographic study.
    Vaksmann G; Pariente-Khayat A; Godart F; Francart C; Rey E; D'Athis P; Pons G; Rey C
    Pediatr Cardiol; 2001; 22(1):11-3. PubMed ID: 11123120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of istaroxime on diastolic stiffness in acute heart failure syndromes: results from the Hemodynamic, Echocardiographic, and Neurohormonal Effects of Istaroxime, a Novel Intravenous Inotropic and Lusitropic Agent: a Randomized Controlled Trial in Patients Hospitalized with Heart Failure (HORIZON-HF) trial.
    Shah SJ; Blair JE; Filippatos GS; Macarie C; Ruzyllo W; Korewicki J; Bubenek-Turconi SI; Ceracchi M; Bianchetti M; Carminati P; Kremastinos D; Grzybowski J; Valentini G; Sabbah HN; Gheorghiade M;
    Am Heart J; 2009 Jun; 157(6):1035-41. PubMed ID: 19464414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Phase 1 Randomized Study of Single Intravenous Infusions of the Novel Nitroxyl Donor BMS-986231 in Healthy Volunteers.
    Cowart D; Venuti RP; Lynch K; Guptill JT; Noveck RJ; Foo SY
    J Clin Pharmacol; 2019 May; 59(5):717-730. PubMed ID: 30703258
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of intravenous nitroglycerin on hemodynamics in infants and children with congestive heart failure.
    Zeng H; Sun L; Li W; Du J
    Chin Med J (Engl); 2000 Apr; 113(4):328-31. PubMed ID: 11775229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rationale and design for the development of a novel nitroxyl donor in patients with acute heart failure.
    Felker GM; Borentain M; Cleland JG; DeSouza MM; Kessler PD; O'Connor CM; Seiffert D; Teerlink JR; Voors AA; McMurray JJV
    Eur J Heart Fail; 2019 Aug; 21(8):1022-1031. PubMed ID: 31168885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of ivabradine in patients with heart failure with preserved ejection fraction: the EDIFY randomized placebo-controlled trial.
    Komajda M; Isnard R; Cohen-Solal A; Metra M; Pieske B; Ponikowski P; Voors AA; Dominjon F; Henon-Goburdhun C; Pannaux M; Böhm M;
    Eur J Heart Fail; 2017 Nov; 19(11):1495-1503. PubMed ID: 28462519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological mechanisms for left ventricular unloading in clinical congestive heart failure. Differential effects of nitroprusside, phentolamine, and nitroglycerin on cardiac function and peripheral circulation.
    Miller RR; Vismara LA; Williams DO; Amsterdam EA; Mason DT
    Circ Res; 1976 Jul; 39(1):127-33. PubMed ID: 819179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stand [Up] and Stand by for New Strategies for Treating Acute Heart Failure.
    Greenberg B; Urey MA
    JACC Heart Fail; 2021 Feb; 9(2):158-160. PubMed ID: 33422436
    [No Abstract]   [Full Text] [Related]  

  • 13. Randomized Trial of Empagliflozin in Nondiabetic Patients With Heart Failure and Reduced Ejection Fraction.
    Santos-Gallego CG; Vargas-Delgado AP; Requena-Ibanez JA; Garcia-Ropero A; Mancini D; Pinney S; Macaluso F; Sartori S; Roque M; Sabatel-Perez F; Rodriguez-Cordero A; Zafar MU; Fergus I; Atallah-Lajam F; Contreras JP; Varley C; Moreno PR; Abascal VM; Lala A; Tamler R; Sanz J; Fuster V; Badimon JJ;
    J Am Coll Cardiol; 2021 Jan; 77(3):243-255. PubMed ID: 33197559
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hemodynamic effects of intravenous nitroglycerin: importance of the delivery system.
    Mutch WA; Culligan JD; Cote DD; Thomson IR
    Anesth Analg; 1982 Nov; 61(11):927-32. PubMed ID: 6814298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel Mitochondria-Targeting Peptide in Heart Failure Treatment: A Randomized, Placebo-Controlled Trial of Elamipretide.
    Daubert MA; Yow E; Dunn G; Marchev S; Barnhart H; Douglas PS; O'Connor C; Goldstein S; Udelson JE; Sabbah HN
    Circ Heart Fail; 2017 Dec; 10(12):. PubMed ID: 29217757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved left ventricular function and topography by prolonged nitroglycerin therapy after acute myocardial infarction.
    Jugdutt BI; Michorowski BL; Tymchak WJ
    Z Kardiol; 1989; 78 Suppl 2():127-9; discussion 142-4. PubMed ID: 2511685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antianginal effects of intravenous nitroglycerin over 24 hours.
    Zimrin D; Reichek N; Bogin KT; Aurigemma G; Douglas P; Berko B; Fung HL
    Circulation; 1988 Jun; 77(6):1376-84. PubMed ID: 3131041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Empagliflozin on Hemodynamics in Patients With Heart Failure and Reduced Ejection Fraction.
    Omar M; Jensen J; Frederiksen PH; Kistorp C; Videbæk L; Poulsen MK; Möller S; Ali M; Gustafsson F; Køber L; Borlaug BA; Schou M; Møller JE
    J Am Coll Cardiol; 2020 Dec; 76(23):2740-2751. PubMed ID: 33272368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of the Oral Soluble Guanylate Cyclase Stimulator: The VICTORIA Trial.
    Armstrong PW; Roessig L; Patel MJ; Anstrom KJ; Butler J; Voors AA; Lam CSP; Ponikowski P; Temple T; Pieske B; Ezekowitz J; Hernandez AF; Koglin J; O'Connor CM
    JACC Heart Fail; 2018 Feb; 6(2):96-104. PubMed ID: 29032136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rationale and design of the hemodynamic, echocardiographic and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure (HORIZON-HF) trial.
    Blair JE; Macarie C; Ruzyllo W; Bacchieri A; Valentini G; Bianchetti M; Pang PS; Harinstein ME; Sabbah HN; Filippatos GS; Gheorghiade M;
    Am J Ther; 2008; 15(3):231-40. PubMed ID: 18496261
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.